"Tosyl Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Toluenesulfonyl compounds with general formula CH3C6H4S(O2)R” widely used to block amino groups in the course of syntheses of drugs and other biologically active compounds.
| Descriptor ID |
D014105
|
| MeSH Number(s) |
D02.455.426.559.389.832.661 D02.886.590.887
|
| Concept/Terms |
Tosyl Compounds- Tosyl Compounds
- Compounds, Tosyl
- Toluenesulfonyl Compounds
- Compounds, Toluenesulfonyl
|
Below are MeSH descriptors whose meaning is more general than "Tosyl Compounds".
Below are MeSH descriptors whose meaning is more specific than "Tosyl Compounds".
This graph shows the total number of publications written about "Tosyl Compounds" by people in this website by year, and whether "Tosyl Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2014 | 1 | 2 | 3 |
| 2017 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tosyl Compounds" by people in Profiles.
-
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021 04 01; 7(4):544-552.
-
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017 02 02; 376(5):417-428.
-
Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015 Feb 01; 33(4):332-9.
-
PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. J Transl Med. 2014 Oct 03; 12:275.
-
Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299. Urol Oncol. 2014 Aug; 32(6):936-7.
-
Novel model to study combined effects of microorganisms and oxidants on development of intestinal necrosis. Surg Infect (Larchmt). 2012 Aug; 13(4):238-44.
-
Does activation of the anti proton, rather than concertedness, determine the stereochemistry of base-catalyzed 1,2-elimination reactions? Anti stereospecificity in E1cB eliminations of ß-3-trifluoromethylphenoxy esters, thioesters, and ketones. J Org Chem. 2012 Mar 16; 77(6):2819-28.
-
Association between leukotriene-modifying agents and suicide: what is the evidence? Drug Saf. 2011 Jul 01; 34(7):533-44.
-
Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic. Mol Endocrinol. 2009 Mar; 23(3):412-21.
-
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol. 2008 Mar 20; 26(9):1532-6.